SoftBank-Backed Noah Medical Prepares $100M Hong Kong IPO to Fuel China Growth
Noah Medical, a US surgical robotics company backed by SoftBank, has started preparations for a Hong Kong initial public offering.
The firm aims to raise more than 100 million US dollars through the listing.
Strategic Move to Tap Asia Capital Markets
Founder Zhang Jian stated that Hong Kong serves as the natural choice due to its status as an international financial center.
The company plans to use the proceeds to expand sales of its robotic systems across mainland China cities including Hangzhou.
Regulatory approval from China's drug regulator was already secured in late 2025, paving the way for broader market entry.
Currently about 90 percent of revenue comes from the United States where the technology has been used on around 15,000 patients.
This IPO plan fits a broader pattern of medtech firms seeking listings in Hong Kong to access regional funding pools.
Longer-Term Implications for Medtech Founders
Over the next 12 months founders may see increased competition as more US robotics companies eye Asian listings amid shifting global capital flows.
Successful execution could accelerate adoption of robotic bronchoscopy tools and benefit hospitals seeking minimally invasive lung diagnostics.
It also highlights how venture-backed healthtech startups must navigate cross-border regulations and market timing to scale effectively.
Early movers in this space gain advantages in building clinical data and partnerships that later entrants may struggle to match.
